Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1957 1
1958 2
1960 2
1961 1
1962 2
1963 2
1964 5
1965 4
1966 1
1969 1
1971 7
1972 1
1973 5
1974 2
1975 6
1976 8
1977 10
1978 12
1979 20
1980 11
1981 17
1982 17
1983 29
1984 22
1985 38
1986 39
1987 40
1988 29
1989 39
1990 48
1991 35
1992 49
1993 45
1994 68
1995 64
1996 78
1997 84
1998 99
1999 79
2000 144
2001 127
2002 156
2003 199
2004 249
2005 328
2006 401
2007 450
2008 517
2009 588
2010 704
2011 777
2012 991
2013 1064
2014 1262
2015 1293
2016 1385
2017 1486
2018 1797
2019 2038
2020 2489
2021 2835
2022 3369
2023 3189
2024 1182

Text availability

Article attribute

Article type

Publication date

Search Results

26,785 results

Results by year

Filters applied: . Clear all
Page 1
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Among authors: cheng y. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
Engineering APOBEC3A deaminase for highly accurate and efficient base editing.
Yang L, Huo Y, Wang M, Zhang D, Zhang T, Wu H, Rao X, Meng H, Yin S, Mei J, Zhang D, Chen X, Lv J, Liu M, Cheng Y, Guan Y, Feng B, Song G, Yi C, Liu M, Zeng F, Wang L, Li D. Yang L, et al. Among authors: cheng y. Nat Chem Biol. 2024 Mar 29. doi: 10.1038/s41589-024-01595-4. Online ahead of print. Nat Chem Biol. 2024. PMID: 38553609
Five undescribed cyclopeptides from Cordyceps militaris.
Yang W, Fu C, Hu BY, Yan YM, Cheng YX. Yang W, et al. Among authors: cheng yx. Phytochemistry. 2024 Apr 9:114074. doi: 10.1016/j.phytochem.2024.114074. Online ahead of print. Phytochemistry. 2024. PMID: 38604324
ICU Resource Strain and Patient Outcomes.
Wang L, Wu Q, Cheng Y. Wang L, et al. Among authors: cheng y. Crit Care Med. 2024 Apr 1;52(4):e208. doi: 10.1097/CCM.0000000000006160. Epub 2024 Mar 14. Crit Care Med. 2024. PMID: 38483232 No abstract available.
Magnetic modulation of lysosomes for cancer therapy.
Li Y, Lv C, Li Z, Chen C, Cheng Y. Li Y, et al. Among authors: cheng y. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Mar-Apr;16(2):e1947. doi: 10.1002/wnan.1947. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024. PMID: 38488191 Review.
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Ren S, Wang X, Han BH, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: cheng y. J Immunother Cancer. 2024 Feb 21;12(2):e007227. doi: 10.1136/jitc-2023-007227. J Immunother Cancer. 2024. PMID: 38388167 Free PMC article. Clinical Trial.
26,785 results
You have reached the last available page of results. Please see the User Guide for more information.